$3.42 Billion is the total value of Nantahala Capital Management's 116 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 168.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| QQQ | New | INVESCO QQQ TRput | $191,478,000 | – | 600,000 | +100.0% | 5.60% | – |
| ESTA | Buy | ESTABLISHMENT LABS HLDGS INC | $128,790,000 | +67.6% | 2,059,654 | +0.9% | 3.76% | +58.0% |
| IWM | New | ISHARES TRcall | $88,376,000 | – | 400,000 | +100.0% | 2.58% | – |
| TLT | New | ISHARES TRput | $81,270,000 | – | 600,000 | +100.0% | 2.38% | – |
| IWM | New | ISHARES TRrussell 2000 etf | $60,481,000 | – | 273,745 | +100.0% | 1.77% | – |
| QURE | Buy | UNIQURE NV | $56,360,000 | -4.7% | 1,672,891 | +2.2% | 1.65% | -10.1% |
| SGMS | Buy | SCIENTIFIC GAMES CORP | $51,813,000 | +426.3% | 1,345,087 | +466.9% | 1.51% | +396.4% |
| TNL | New | TRAVEL PLUS LEISURE CO | $51,168,000 | – | 836,626 | +100.0% | 1.50% | – |
| QURE | Buy | UNIQURE NVcall | $50,535,000 | +25.7% | 1,500,000 | +34.8% | 1.48% | +18.6% |
| Buy | APTOSE BIOSCIENCES INC | $46,240,000 | +45.2% | 7,738,892 | +6.4% | 1.35% | +37.0% | |
| CAR | New | AVIS BUDGET GROUP | $45,236,000 | – | 623,600 | +100.0% | 1.32% | – |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $44,774,000 | +11.9% | 2,002,410 | +11.3% | 1.31% | +5.6% |
| ARKG | New | ARK ETF TRcall | $44,365,000 | – | 500,000 | +100.0% | 1.30% | – |
| SFT | Buy | SHIFT TECHNOLOGIES INCcl a | $41,411,000 | +32.2% | 5,006,840 | +32.2% | 1.21% | +24.6% |
| CUE | Buy | CUE BIOPHARMA INC | $32,989,000 | +5.2% | 2,703,983 | +7.9% | 0.96% | -0.8% |
| RMR | Buy | RMR GROUP INCcl a | $26,490,000 | +177.7% | 649,096 | +162.8% | 0.77% | +161.5% |
| EXAS | Buy | EXACT SCIENCES CORPput | $26,356,000 | +32.6% | 200,000 | +33.3% | 0.77% | +25.0% |
| MILE | New | METROMILE INC | $25,030,000 | – | 2,432,490 | +100.0% | 0.73% | – |
| CERC | Buy | CERECOR INC | $23,106,000 | +40.4% | 7,650,928 | +22.7% | 0.68% | +32.4% |
| CRIS | Buy | CURIS INC | $18,822,000 | +40.7% | 1,662,711 | +1.8% | 0.55% | +32.9% |
| TDOC | New | TELADOC HEALTH INCput | $18,175,000 | – | 100,000 | +100.0% | 0.53% | – |
| FTOC | New | FTAC OLYMPUS ACQUISITION COR | $15,949,000 | – | 1,508,889 | +100.0% | 0.47% | – |
| PAYA | Buy | PAYA HOLDINGS INC | $15,280,000 | +3.2% | 1,394,116 | +26.7% | 0.45% | -2.6% |
| VG | Buy | VONAGE HLDGS CORPcall | $14,775,000 | +129.5% | 1,250,000 | +150.0% | 0.43% | +117.1% |
| Buy | DARIOHEALTH CORP | $14,449,000 | +70.2% | 750,194 | +26.2% | 0.42% | +60.5% | |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $12,909,000 | +9.7% | 2,561,334 | +37.3% | 0.38% | +3.3% |
| ZVO | Buy | ZOVIO INC | $12,551,000 | -6.8% | 3,091,286 | +8.8% | 0.37% | -12.0% |
| SPCE | New | VIRGIN GALACTIC HOLDINGS INCcall | $12,252,000 | – | 400,000 | +100.0% | 0.36% | – |
| HOOK | New | HOOKIPA PHARMA INC | $12,105,000 | – | 900,000 | +100.0% | 0.35% | – |
| RDI | Buy | READING INTL INCcl a | $11,760,000 | +18.1% | 2,118,875 | +6.8% | 0.34% | +11.3% |
| HERAU | New | FTAC HERA ACQUISITION CORPunit 02/28/2026 | $9,990,000 | – | 1,000,000 | +100.0% | 0.29% | – |
| FTAAU | New | FTAC ATHENA ACQUISITION CORPunit 99/99/9999 | $10,000,000 | – | 1,000,000 | +100.0% | 0.29% | – |
| FTPAU | New | FTAC PARNASSUS ACQUISITN CORunit 03/10/2026 | $9,930,000 | – | 1,000,000 | +100.0% | 0.29% | – |
| ARYA | Buy | ARYA SCIENCES ACQUISITION CO | $9,739,000 | +28.2% | 706,770 | +1.0% | 0.28% | +21.3% |
| HARP | New | HARPOON THERAPEUTICS INC | $9,473,000 | – | 452,813 | +100.0% | 0.28% | – |
| IKNA | New | IKENA ONCOLOGY INC | $9,181,000 | – | 325,000 | +100.0% | 0.27% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INCcall | $7,740,000 | – | 300,000 | +100.0% | 0.23% | – |
| New | PAR TECHNOLOGY CORPnote 2.875% 4/1 | $7,506,000 | – | 6,000,000 | +100.0% | 0.22% | – | |
| XGN | New | EXAGEN INC | $6,551,000 | – | 374,315 | +100.0% | 0.19% | – |
| LVTX | New | LAVA THERAPEUTICS NV | $5,791,000 | – | 381,227 | +100.0% | 0.17% | – |
| RILY | New | B. RILEY FINANCIAL INC | $5,724,000 | – | 101,532 | +100.0% | 0.17% | – |
| DVD | Buy | DOVER MOTORSPORTS INC | $5,350,000 | +24.4% | 2,597,086 | +37.0% | 0.16% | +17.3% |
| ACET | Buy | ADICET BIO INC | $5,178,000 | +7.1% | 395,875 | +15.1% | 0.15% | +0.7% |
| RGS | New | REGIS CORP MINNput | $5,024,000 | – | 400,000 | +100.0% | 0.15% | – |
| ARYD | New | ARYA SCIENCES ACQU CORP IVcl a | $4,189,000 | – | 400,000 | +100.0% | 0.12% | – |
| IMAC | New | IMAC HLDGS INC | $4,125,000 | – | 2,500,000 | +100.0% | 0.12% | – |
| ROCRU | New | ROTH CH ACQUISITION III COunit 02/26/2026 | $4,000,000 | – | 400,000 | +100.0% | 0.12% | – |
| BRPMU | New | B RILEY PRINCIPAL 150 MERGERunit 99/99/9999 | $3,750,000 | – | 375,000 | +100.0% | 0.11% | – |
| MILEW | New | METROMILE INC*w exp 02/09/202 | $3,405,000 | – | 524,964 | +100.0% | 0.10% | – |
| SFT | New | SHIFT TECHNOLOGIES INCcall | $3,328,000 | – | 400,000 | +100.0% | 0.10% | – |
| HCAQ | New | HEALTHCOR CATALIO ACQU CORP | $2,906,000 | – | 290,596 | +100.0% | 0.08% | – |
| New | TELIGENT INC NEW | $2,584,000 | – | 4,155,045 | +100.0% | 0.08% | – | |
| ANGN | New | ANGION BIOMEDICA CORP | $2,259,000 | – | 125,000 | +100.0% | 0.07% | – |
| FTOCW | New | FTAC OLYMPUS ACQUISITION COR*w exp 08/28/202 | $2,035,000 | – | 333,327 | +100.0% | 0.06% | – |
| CELC | New | CELCUITY INC | $1,912,000 | – | 133,367 | +100.0% | 0.06% | – |
| FVAM | New | 5 01 ACQUISITION CORP | $1,862,000 | – | 186,650 | +100.0% | 0.05% | – |
| BOLT | New | BOLT BIOTHERAPEUTICS INC | $1,646,000 | – | 50,000 | +100.0% | 0.05% | – |
| KTRA | Buy | KINTARA THERAPEUTICS INC | $1,571,000 | +350.1% | 902,677 | +230.7% | 0.05% | +318.2% |
| AAN | New | THE AARONS COMPANY INC | $899,000 | – | 35,026 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
About Nantahala Capital Management
Nantahala Capital Management is a hedge fund that was founded in 2004 by Wil Harkey. The firm is headquartered in Connecticut and has additional offices in New York and North Carolina. Nantahala Capital Management primarily invests in the technology, healthcare, and consumer sectors. The firm has a long-term investment approach and seeks to identify undervalued companies with strong growth potential.
Wil Harkey serves as the CEO and Chief Investment Officer of Nantahala Capital Management. He has over 20 years of experience in the finance industry and previously worked at Goldman Sachs and Maverick Capital. In addition to Harkey, the firm's leadership team includes COO and General Counsel, David Kozak, and CFO, Michael Kozak.
Nantahala Capital Management has a strong track record of generating positive returns for its investors. The firm's flagship fund, the Nantahala Fund, has delivered an annualized return of over 20% since its inception in 2006. The firm's success can be attributed to its disciplined investment approach and focus on long-term value creation.
Overall, Nantahala Capital Management is a well-respected hedge fund with a talented leadership team and a strong track record of performance. However, as with any investment, it is important for investors to conduct their own due diligence and carefully consider the risks before investing in the firm's funds.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ISHARES TR | 42 | Q3 2023 | 27.2% |
| CODEXIS INC | 42 | Q3 2023 | 3.9% |
| PATHWARD FINANCIAL INC | 35 | Q3 2023 | 6.3% |
| SCIENTIFIC GAMES CORP | 34 | Q3 2022 | 5.3% |
| DOVER MOTORSPORTS INC | 34 | Q3 2021 | 0.5% |
| GOLDEN ENTMT INC | 33 | Q3 2023 | 2.1% |
| QAD INC | 32 | Q3 2021 | 2.6% |
| SCIENTIFIC GAMES CORP | 31 | Q4 2021 | 7.7% |
| DOLBY LABORATORIES INC | 31 | Q4 2020 | 5.6% |
| LINCOLN EDL SVCS CORP | 31 | Q4 2021 | 0.7% |
View Nantahala Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AYTU BIOPHARMA, INC | June 16, 2023 | 1,086,812 | 19.7% |
| Acer Therapeutics Inc. | February 14, 2023 | 1,226,191 | 7.5% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 4,611,302 | 7.5% |
| AKUMIN INC. | February 14, 2023 | 2,206,960 | 2.5% |
| ALTA EQUIPMENT GROUP INC. | February 14, 2023 | 1,188,985 | 3.7% |
| Apollo Endosurgery, Inc. | February 14, 2023 | 4,056,627 | 9.9% |
| Autolus Therapeutics plc | February 14, 2023 | 7,782,018 | 4.7% |
| Bioventus Inc. | February 14, 2023 | 3,168,574 | 5.1% |
| CATALYST BIOSCIENCES, INC. | February 14, 2023 | 438,055 | 1.4% |
| Drive Shack Inc. | February 14, 2023 | 6,500,000 | 7.0% |
View Nantahala Capital Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-21 |
| 4 | 2024-03-15 |
| SC 13G | 2024-03-11 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Nantahala Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.